LLY · News · 20260913N
Competition and market share - oral GLP-1
ELI LILLY & Co · 2026-09-13 · Importance 26 · Surprise 24 · In source text
Novo Nordisk launched its Wegovy oral pill in early 2026, competing directly with Eli Lilly’s Foundayo oral GLP-1 treatment. Third-party reporting says Wegovy has been very well received, while Foundayo has gained traction more slowly. The comparison indicates competitive pressure on Lilly’s positioning and adoption in the oral weight-loss market.
Key facts
- Eli Lilly quickly followed Novo Nordisk's early-2026 launch with a pill called Foundayo. source
- Eli Lilly's pill Foundayo has been slower to gain traction. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | probable | — | Eli Lilly quickly followed Novo Nordisk's early-2026 launch with a pill called Foundayo. |